AlphAIAlphAI — Financial news for AI agents
SEC EDGARJUN 21 min read$LGND

Reardon Andrew sold $1.1M of LGND

Reardon Andrew (CLO & Secretary) sold 5,000 shares of LIGAND PHARMACEUTICALS INC (LGND) at an average of $227.06 ($223.95–$230.41, $1.14M total) across 7 trades on 2026-06-01 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Reardon Andrew
Published Jun 2, 2026, 10:22 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 28, 2026, 4:03 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$LGND
Bearish
medium confidence
Mentioned
$LGND
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$LGNDBearishLow
01

Why it matters

The disclosed sale may prompt short‑term price adjustments but is unlikely to affect long‑term valuation.

02

Market read

Primary insider sale filing; modest relevance for traders monitoring LGND's short‑term price action.

03

What to watch

Potential upcoming corporate actions or financing needs not disclosed in the filing.

Relevance 5/10Novelty 3/10Timing: post‑filing today

Background

Form 4 filing discloses insider transactions required by the SEC; such filings are primary sources of new information.

Company-level read

Ticker impact

$LGNDBearishMedium confidence
Context

CLO & Secretary sold 5,000 shares for $1.135M via a 10b5‑1 plan on 2026‑06‑01

Expected impact

likely downward pressure as market prices in the insider sell

Evidence & confidence

The sale represents a $1.1M disposition by a senior officer, which typically signals modest negative sentiment.

Market effects

Sector

Minimal impact on biotech sector; insider sales are routine and not indicative of broader trends.

Regional

No regional effect; the filing is specific to LGND.

Global

Limited global relevance; only affects LGND shareholders.

Counterpoint

What could challenge this read

The sale could be a routine liquidity event unrelated to company fundamentals, so price may remain stable.

Key entities

  • Company
    Ligand Pharmaceuticals Inc.

    Biotech firm listed on NASDAQ under ticker LGND.

  • Insider
    Reardon Andrew

    Chief Legal Officer & Secretary of Ligand Pharmaceuticals.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

LGND insider trading history →

Related articles

SEP 27
$LGNDMed

Ligand (LGND)-AvenCell Deal: Most of the Funding Is Tied to Milestones

Ligand Pharmaceuticals (LGND) announced a $47M financing deal with AvenCell Therapeutics, including $6M for Series C funding and $41M for drug development, tied to milestones. Ligand aims for mid-single-digit to low-double-digit royalties on AvenCell's sales. The company's royalty revenue grew 32% YoY to $48M in Q2, with a target of $225M-$250M for 2026. Ligand has $1.36B in cash and $700M for further investments.

insidermonkey.com2 min
SEP 24
$LGNDMed

Ligand and AvenCell Therapeutics Enter Financing Agreement to Advance Pipeline of Next-Generation CAR-T Therapies for Up to $47 Million

LIGAND PHARMACEUTICALS INC (LGND) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 Ligand and AvenCell Therapeutics Enter Financing Agreement to Advance Pipeline of Next-Generation CAR-T Therapies for Up to $47 Million JUPITER, Fla., September 24, 2026 – Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it has entered into a f

SEC EDGAR 8-K1 min
SEP 4
$LGNDHighAI 8/10

Ligand Pharmaceuticals (LGND): Massive XOMA Acquisition Doubles The Royalty Book

Ligand Pharmaceuticals (LGND) reported Q2 2026 revenue of $63.7M, up 32% YoY, driven by royalty revenue growth. The company acquired XOMA Royalty, doubling its royalty portfolio and adding $700M in convertible debt. Ligand raised its full-year adjusted earnings guidance, but expenses increased due to the acquisition and other costs. The stock trades at a forward P/E of 25.19.

insidermonkey.com3 min
AUG 13
$LGNDHighAI 9/10

Ligand (LGND) Q2 2026 Earnings Call Transcript

Ligand Pharmaceuticals (LGND) reported Q2 2026 revenue of $63.7M, up 34%, driven by $48.0M royalty revenue (+32%). Adjusted diluted EPS was $2.37 (+48%). 2026 guidance raised to adjusted EPS $9.00-$9.50 and revenue $270M-$310M. Cash and short-term investments were $1.36B after a $700M convertible note. The XOMA Royalty acquisition added 120 assets.

fool.com6 min
AUG 8
$LGNDMed

Ligand Pharmaceuticals Incorporated Q2 2026 Earnings Call Summary

Ligand Pharmaceuticals reported Q2 2026 results and discussed its XOMA Royalty acquisition, adding 120+ assets and extending cash flow duration through 2040. Management cited 32% YoY royalty revenue growth and expects 2026 royalty revenue of $225M-$250M with cash opex halved since 2022. Ligand issued a $700M zero-coupon convertible, raised 2026 adjusted EPS guidance to $9.00-$9.50, and expects accretion from XOMA in 2H26 and 2027.

yahoo.com7 min